Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
New Perspectives in Treating Thyroid Eye Disease (TED)
Diagnostic Challenges of TED: What Eye Care Specialists Need to Know
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Prem Subramanian, MD, PhD
Chief, Neuro-Ophthalmology
Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology
Vice Chair for Academic Affairs, Ophthalmology
Professor with Tenure in Ophthalmology, Neurology, and Neurosurgery
University of Colorado School of Medicine
Aurora, CODr. Subramanian has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Neurophth, Horizon/ Amgen, GenSight Biologics, Tourmaline Bio, Viridian, Immunovant, Invex
Consulting Fees: Amgen/ Horizon, ACEL YRIN, Alexion, argenx, Neurophtn, Viridian, Tourmaline Bio, Invex, KriyaFaculty:
Fatemeh Rajaii, MD, PhD
Ophthalmic Plastic and Reconstructive Surgery
Associate Professor of Ophthalmology
Wilmer Eye Institute
Baltimore, MDDr. Rajaii has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Immunovant, Viridian, Roche (pending)
Consulting Fees: Amgen, AcelyrinTerry J. Smith, MD
Frederick G.L. Huetwell Professor of Ophthalmology and Visual Sciences
Professor, Department of Internal Medicine
Kellogg Eye Center
Ann Arbor, MIDr. Smith has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Receives royalties: Patent royalties through Lundquist/ UCLA
Consulting Fees: Amgen, Viridian, Argenx, Minghui, LassenSelina McGee, OD, FAAO
CEO/Owner BeSpoke Vision
President Intrepid Eye Society
Board of Examiners Oklahoma Optometry
Edmond, OKDr. McGee has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Aldeyra, Allergan, Alcon, Avellino, Bruder, Horizon, Novartis, Sun, Versant, Kala, RVL, Tarsus, Science Based Health, Thea, Topcon, Zeiss, Lumenis, Bausch & Lomb, Cynosure, Optovue, Dompe, Oyster PointReviewers/Content Planners/Authors:
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Stephanie Wenick, MPhil, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss the burden of traditional medical and surgical treatments for thyroid eye disease (TED), including adverse effects and routes of administration.
- Identify the various clinical presentations of TED and considerations for clinical trial enrollment.
- Examine underlying pathogenic regulators of TED and their potential as immunologic treatment targets
- Explore the clinical efficacy and safety data for current and emerging medical therapies for TED
Target Audience
This activity has been designed to meet the educational needs of ophthalmologists, endocrinologists, and optometrists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with thyroid eye disease.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 credit nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 9/30/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Tourmaline Bio, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
